Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15322764rdf:typepubmed:Citationlld:pubmed
pubmed-article:15322764lifeskim:mentionsumls-concept:C0005699lld:lifeskim
pubmed-article:15322764lifeskim:mentionsumls-concept:C0023473lld:lifeskim
pubmed-article:15322764lifeskim:mentionsumls-concept:C0022688lld:lifeskim
pubmed-article:15322764lifeskim:mentionsumls-concept:C0040715lld:lifeskim
pubmed-article:15322764lifeskim:mentionsumls-concept:C1522702lld:lifeskim
pubmed-article:15322764lifeskim:mentionsumls-concept:C0439677lld:lifeskim
pubmed-article:15322764lifeskim:mentionsumls-concept:C1524062lld:lifeskim
pubmed-article:15322764lifeskim:mentionsumls-concept:C0599718lld:lifeskim
pubmed-article:15322764lifeskim:mentionsumls-concept:C0599813lld:lifeskim
pubmed-article:15322764lifeskim:mentionsumls-concept:C0599893lld:lifeskim
pubmed-article:15322764pubmed:issue12lld:pubmed
pubmed-article:15322764pubmed:dateCreated2004-11-4lld:pubmed
pubmed-article:15322764pubmed:abstractTextWe encountered a patient in blast crisis (BC) with chronic myelogenous leukemia (CML) who showed immunophenotypic features similar to those previously described in acute myeloid/natural killer (NK) cell precursor leukemia. The blasts were positive for CD7, CD33, CD34, and CD56. Cytogenetic analysis disclosed a Philadelphia chromosome (Ph) and t(3;7)(q26;q21). Molecular analysis did not detect any EVI1/CDK6 chimeric transcript generated by t(3;7)(q26;q21), but did indicate overexpression of EVI1, which occurs frequently in progression to myeloid BC in CML. Three cases of myeloid/NK cell precursor BC in CML have been reported, but this case is the first to present with Ph and EVI1 abnormality. These observations suggested that a myeloid/NK cell precursor might have been involved in the Ph-positive clone and have been a target for blastic transformation of CML, although EVI1 expression is not specific for transformation to BC from myeloid/NK lineage.lld:pubmed
pubmed-article:15322764pubmed:languageenglld:pubmed
pubmed-article:15322764pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15322764pubmed:citationSubsetIMlld:pubmed
pubmed-article:15322764pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15322764pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15322764pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15322764pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15322764pubmed:statusMEDLINElld:pubmed
pubmed-article:15322764pubmed:monthDeclld:pubmed
pubmed-article:15322764pubmed:issn0939-5555lld:pubmed
pubmed-article:15322764pubmed:authorpubmed-author:HaradaMineMlld:pubmed
pubmed-article:15322764pubmed:authorpubmed-author:TakaseKenKlld:pubmed
pubmed-article:15322764pubmed:authorpubmed-author:MiyamotoToshi...lld:pubmed
pubmed-article:15322764pubmed:authorpubmed-author:NagafujiKojiKlld:pubmed
pubmed-article:15322764pubmed:authorpubmed-author:HenzanHidehoHlld:pubmed
pubmed-article:15322764pubmed:authorpubmed-author:FukudaTakahir...lld:pubmed
pubmed-article:15322764pubmed:authorpubmed-author:YoshimotoGoic...lld:pubmed
pubmed-article:15322764pubmed:authorpubmed-author:OkedaAkiAlld:pubmed
pubmed-article:15322764pubmed:authorpubmed-author:NagasakiYojiYlld:pubmed
pubmed-article:15322764pubmed:authorpubmed-author:HiranoGenGlld:pubmed
pubmed-article:15322764pubmed:authorpubmed-author:TanimotoTetsu...lld:pubmed
pubmed-article:15322764pubmed:issnTypePrintlld:pubmed
pubmed-article:15322764pubmed:volume83lld:pubmed
pubmed-article:15322764pubmed:ownerNLMlld:pubmed
pubmed-article:15322764pubmed:authorsCompleteYlld:pubmed
pubmed-article:15322764pubmed:pagination784-8lld:pubmed
pubmed-article:15322764pubmed:dateRevised2010-9-15lld:pubmed
pubmed-article:15322764pubmed:meshHeadingpubmed-meshheading:15322764...lld:pubmed
pubmed-article:15322764pubmed:meshHeadingpubmed-meshheading:15322764...lld:pubmed
pubmed-article:15322764pubmed:meshHeadingpubmed-meshheading:15322764...lld:pubmed
pubmed-article:15322764pubmed:meshHeadingpubmed-meshheading:15322764...lld:pubmed
pubmed-article:15322764pubmed:meshHeadingpubmed-meshheading:15322764...lld:pubmed
pubmed-article:15322764pubmed:meshHeadingpubmed-meshheading:15322764...lld:pubmed
pubmed-article:15322764pubmed:meshHeadingpubmed-meshheading:15322764...lld:pubmed
pubmed-article:15322764pubmed:meshHeadingpubmed-meshheading:15322764...lld:pubmed
pubmed-article:15322764pubmed:meshHeadingpubmed-meshheading:15322764...lld:pubmed
pubmed-article:15322764pubmed:meshHeadingpubmed-meshheading:15322764...lld:pubmed
pubmed-article:15322764pubmed:meshHeadingpubmed-meshheading:15322764...lld:pubmed
pubmed-article:15322764pubmed:meshHeadingpubmed-meshheading:15322764...lld:pubmed
pubmed-article:15322764pubmed:meshHeadingpubmed-meshheading:15322764...lld:pubmed
pubmed-article:15322764pubmed:meshHeadingpubmed-meshheading:15322764...lld:pubmed
pubmed-article:15322764pubmed:meshHeadingpubmed-meshheading:15322764...lld:pubmed
pubmed-article:15322764pubmed:year2004lld:pubmed
pubmed-article:15322764pubmed:articleTitleMyeloid/natural killer cell blast crisis representing an additional translocation, t(3;7)(q26;q21) in Philadelphia-positive chronic myelogenous leukemia.lld:pubmed
pubmed-article:15322764pubmed:affiliationMedicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.lld:pubmed
pubmed-article:15322764pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15322764pubmed:publicationTypeCase Reportslld:pubmed
pubmed-article:15322764pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed